<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03614364</url>
  </required_header>
  <id_info>
    <org_study_id>2017-11-082</org_study_id>
    <nct_id>NCT03614364</nct_id>
  </id_info>
  <brief_title>Combination of Nanoxel and Herzuma in Salivary Duct Carcinoma</brief_title>
  <official_title>Combination of Nanoxel and Herzuma as First-line Chemotherapy in Patients With Metastatic Salivary Duct Carcinoma : Open Label Single Arm Multicenter Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Study outline This is a multicenter, single-arm, phase II trial to evaluate the efficacy&#xD;
           and safety of nanoxel plus herzuma combination chemotherapy in patients with metastatic&#xD;
           salivary ductal cancer. Approximately 41 patients will be enrolled. Treatment will be&#xD;
           continued until disease progression or unacceptable toxicities. Response evaluation will&#xD;
           be performed every 2 cycles.&#xD;
&#xD;
        2. Dosing &amp; Treatment schedule D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma&#xD;
           8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV&#xD;
           over 30mins (since 2 cycle) repeated every 3 weeks (In case of discontinuation of&#xD;
           nanoxel without progression, single agent herzuma can be administered until progression)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 20, 2018</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>about 24months</time_frame>
    <description>according to RECIST version 1.1</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">41</enrollment>
  <condition>Salivary Duct Carcinoma</condition>
  <arm_group>
    <arm_group_label>nanoxel and herzuma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nanoxel</intervention_name>
    <description>D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks</description>
    <arm_group_label>nanoxel and herzuma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>herzuma</intervention_name>
    <description>D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks</description>
    <arm_group_label>nanoxel and herzuma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically-confirmed HER2 positive (immunohistochemistry [IHC] 3+, and/or&#xD;
             fluorescence in situ hybridization[FISH] positive with ≥ two-fold amplification)&#xD;
             salivary duct carcinoma(SDC), and other salivary gland carcinomas which are similar to&#xD;
             SDC in histopathological findings, including adenocarcinoma, not otherwise specified,&#xD;
             acinic cell carcinoma, squamous cell carcinoma, anaplastic carcinoma, high grade&#xD;
             mucoepidermoid carcinoma, and carcinoma ex pleomorphic adenoma&#xD;
&#xD;
          -  stage IV or recurrent cancer&#xD;
&#xD;
          -  age ≥ 20 years&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  At least one measurable tumor lesion according to RECIST 1.1&#xD;
&#xD;
          -  Expected survival for approximately 12 weeks or longer&#xD;
&#xD;
          -  No prior systemic chemotherapy&#xD;
&#xD;
          -  At least 4 weeks later after surgery or radiotherapy&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe or unstable cardiac disease, including (for example) coronary artery disease&#xD;
             requiring increased doses of anti-anginal medication and/or coronary angioplasty&#xD;
             (including stent placement) within the preceding 24 months(congestive heart failure&#xD;
             NYHA III or IV, unstable angina pectoris, history of myocardial infarction within the&#xD;
             last twelve months, significant arrhythmias)&#xD;
&#xD;
          -  Uncontrolled systemic illness such as DM, hypertension, hypothyroidism and infection&#xD;
&#xD;
          -  Pregnant and nursing women (women of reproductive potential have to agree to use an&#xD;
             effective contraceptive method)&#xD;
&#xD;
          -  Current, known CNS malignancy (history of completely resected or irradiated brain&#xD;
             metastases by WBRT or stereotactic radiosurgery allowed)&#xD;
&#xD;
          -  Patients with alcohol abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myung-Ju Ahn, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 30, 2018</study_first_submitted>
  <study_first_submitted_qc>July 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>August 8, 2021</last_update_submitted>
  <last_update_submitted_qc>August 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Myung-Ju Ahn</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

